Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Circulating levels of miR-20b-5p are associated with survival in cardiogenic shock.

Journal of molecular and cellular cardiology plus·2025

Same author

Validation of a biomarker-based mortality score for cardiogenic shock patients: Comparison with a clinical risk score.

ESC heart failure·2025

Same author

Risk of Major Adverse Cardiovascular Events in Home Dialysis Compared With In-Center Hemodialysis.

Clinical journal of the American Society of Nephrology : CJASN·2025

Same author

Risk of Major Adverse Cardiovascular Events in Home Dialysis Compared With In-Center Hemodialysis.

Clinical journal of the American Society of Nephrology : CJASN·2024

Same author

Serum Chloride and the Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload: A Post Hoc Analysis From the ADVOR Trial.

Circulation. Heart failure·2024

Same author

Quantifying Hemodynamic Cardiac Stress and Cardiomyocyte Injury in Normotensive and Hypertensive Acute Heart Failure.

Biomedicines·2024

Same journal

Update on Current Care Guideline: Psoriasis (skin and joints).

Duodecim; laaketieteellinen aikakauskirja·2017

Same journal

FOUR score in monitoring the level of consciousness of an intensive care patient: first experience of the use of the Finnish language version.

Duodecim; laaketieteellinen aikakauskirja·2017

Same journal

Discussing a serious illness with a patient and family.

Duodecim; laaketieteellinen aikakauskirja·2017

Same journal

Invasive treatment of superficial veins of the lower extremities.

Duodecim; laaketieteellinen aikakauskirja·2017

Same journal

When should a drain be left in the abdominal cavity upon surgery?

Duodecim; laaketieteellinen aikakauskirja·2017

Same journal

Diagnostics and current care of myasthenia gravis.

Duodecim; laaketieteellinen aikakauskirja·2017

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

A Mouse 5/6^th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

[Cardiorenal syndrome].

Johan Lassus¹, Mikko Haapio

¹HYKS:n kardiologian vastuuyksikkö, PL 340, 00029 HUS.

Duodecim; Laaketieteellinen Aikakauskirja

|September 23, 2009

Summary

This summary is machine-generated.

Cardiorenal syndrome involves heart-kidney interactions where one organ

More Related Videos

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

Related Experiment Videos

Last Updated: Jun 20, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

A Mouse 5/6^th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Normothermic Cardiac Arrest and Cardiopulmonary Resuscitation: A Mouse Model of Ischemia-Reperfusion Injury

Published on: August 30, 2011

Area of Science:

Cardiology
Nephrology
Cardiorenal Medicine

Context:

Cardiorenal syndrome describes the complex interplay between cardiac and renal systems.
Existing definitions lack precision, necessitating a new classification.
Clinical examples include cardiac events in dialysis patients and renal issues in cardiac patients.

Purpose:

To introduce a novel classification for cardiorenal syndrome.
To provide a more precise definition of the condition.
To elucidate the multifaceted interactions between the heart and kidneys.

Summary:

A new classification for cardiorenal syndrome has been established.
This syndrome involves bidirectional impairment between the heart and kidneys.
Manifestations include cardiac events in renal patients and vice versa, alongside diuretic resistance.

Impact:

The new classification offers a refined understanding of cardiorenal syndrome.
It facilitates more accurate diagnosis and management strategies.
Improved patient outcomes are anticipated through better-defined therapeutic targets.